Quote:

---

Immunotherapy-related cognitive impairment after CAR T cell therapy in mice

Would that be something, Leronlimab could help?

---

Quote:

---

Single-nucleus sequencing studies of human frontal lobe from patients with or without previous CAR T cell therapy for brainstem tumors confirmed reactive states of microglia and oligodendrocytes following treatment. In mice, transient microglial depletion or CCR3 chemokine receptor blockade rescued oligodendroglial deficits and cognitive performance in a behavioral test of attention and short-term memory function following CAR T cell therapy. Taken together, these findings illustrate targetable neural-immune mechanisms underlying immunotherapy-related cognitive impairment.
https://www.cell.com/cell/fulltext/S0092-8674...all%3Dtrue

---

The cognitive decline is inflammation related, so yes. If our cancer trial results are equivalent to CAR-T results than CAR-T is unnecessary. If CAR-T results are better than leronlimab can be added for cognition repair.